Why Your IRA Could Crash on January 16th?
China will attack Taiwan as soon as January 16th, 2023.

The stock market will crash at least 35% when China makes their move.
Here are the 3 steps to protect your portfolio
Eric Benevich net worth and biography

Eric Benevich Biography and Net Worth

Eric Benevich was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine Biosciences product portfolio. Previously, Mr. Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015, serving most recently as Vice President of Marketing where he was responsible for NUEDEXTA® and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel®, Epogen® and Prilosec®. Mr. Benevich has a BBA in International Business from Washington State University.

What is Eric Benevich's net worth?

The estimated net worth of Eric Benevich is at least $1.98 million as of November 30th, 2022. Mr. Benevich owns 15,643 shares of Neurocrine Biosciences stock worth more than $1,975,867 as of December 1st. This net worth evaluation does not reflect any other investments that Mr. Benevich may own. Additionally, Mr. Benevich receives a salary of $805,000.00 as Insider at Neurocrine Biosciences. Learn More about Eric Benevich's net worth.

How old is Eric Benevich?

Mr. Benevich is currently 57 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 64 years old. Learn More on Eric Benevich's age.

What is Eric Benevich's salary?

As the Insider of Neurocrine Biosciences, Inc., Mr. Benevich earned a total compensation package of $5,805,086.00 in 2021. Mr. Benevich earned a salary of $534,900.00, a bonus of $213,960.00, stock awards of $2,375,068.00, options awards of $2,625,019.00, and other compensation of $56,139.00.There are 3 executives that earn more than Mr. Benevich. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $1,580,000.00 per year. Learn More on Eric Benevich's salary.

How do I contact Eric Benevich?

The corporate mailing address for Mr. Benevich and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected] Learn More on Eric Benevich's contact information.

Has Eric Benevich been buying or selling shares of Neurocrine Biosciences?

During the past quarter, Eric Benevich has sold $9,939,443.89 in shares of Neurocrine Biosciences stock. Most recently, Eric Benevich sold 50,000 shares of the business's stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $125.90, for a transaction totalling $6,295,000.00. Following the completion of the sale, the insider now directly owns 15,643 shares of the company's stock, valued at $1,969,453.70. Learn More on Eric Benevich's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 24 times. They sold a total of 252,104 shares worth more than $26,298,025.59. The most recent insider tranaction occured on November, 30th when insider Eric Benevich sold 50,000 shares worth more than $6,295,000.00. Insiders at Neurocrine Biosciences own 4.4 % of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 11/30/2022.

Eric Benevich Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2022Sell50,000$125.90$6,295,000.0015,643View SEC Filing Icon  
11/10/2022Sell100$125.36$12,536.0015,643View SEC Filing Icon  
11/8/2022Sell24,593$125.33$3,082,240.6915,643View SEC Filing Icon  
10/17/2022Sell4,960$110.82$549,667.2015,643View SEC Filing Icon  
8/16/2021Sell5,628$89.62$504,381.36View SEC Filing Icon  
11/12/2020Sell2,257$90.71$204,732.4717,405View SEC Filing Icon  
11/2/2020Sell20,595$96.53$1,988,035.3535,969View SEC Filing Icon  
4/15/2020Sell8,632$94.65$817,018.80View SEC Filing Icon  
7/15/2019Sell5,835$87.44$510,212.4014,910View SEC Filing Icon  
6/1/2018Sell12,350$97.34$1,202,149.0016,690View SEC Filing Icon  
See Full Table

Eric Benevich Buying and Selling Activity at Neurocrine Biosciences

This chart shows Eric Benevich's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $126.31
Low: $125.65
High: $129.29

50 Day Range

MA: $114.32
Low: $100.57
High: $127.06

2 Week Range

Now: $126.31
Low: $71.88
High: $129.29

Volume

654,328 shs

Average Volume

758,217 shs

Market Capitalization

$12.14 billion

P/E Ratio

221.60

Dividend Yield

N/A

Beta

0.53
Why Your IRA Could Crash on January 16th?
China will attack Taiwan as soon as January 16th, 2023.

The stock market will crash at least 35% when China makes their move.
Here are the 3 steps to protect your portfolio